Division of Gastroenterology, Long Island Jewish Medical Center, North Shore University-Long Island Jewish Health System, 270-05 76th Avenue, New Hyde Park, NY 11040, USA.
Trends Endocrinol Metab. 2010 Nov;21(11):668-75. doi: 10.1016/j.tem.2010.08.003. Epub 2010 Sep 27.
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in the Western world. It can lead to cirrhosis and hepatocellular cancer, and is independently associated with an increased risk of death due to cardiovascular and liver diseases. Over the past 5 years, numerous advances in understanding its pathogenesis have been made, providing a rationale for translation of this information into clinical trials. Although the optimum therapy is still awaited, there is strong evidence to support the use of vitamin E in selected subjects. Many other potential therapeutic options are now available. In this paper, we review the status of both current and emerging therapeutic strategies for patients with NASH.
非酒精性脂肪性肝炎（NASH）是西方世界最常见的慢性肝病病因。它可导致肝硬化和肝细胞癌，并与心血管疾病和肝脏疾病导致的死亡风险增加独立相关。在过去的 5 年中，人们对其发病机制的理解取得了许多进展，为将这些信息转化为临床试验提供了依据。虽然最佳治疗方法仍在等待中，但有强有力的证据支持在选定的患者中使用维生素 E。现在有许多其他潜在的治疗选择。本文综述了 NASH 患者现有和新兴治疗策略的现状。
